Glazer Capital LLC Makes New $692,000 Investment in Catalent, Inc. (NYSE:CTLT)

Glazer Capital LLC acquired a new stake in Catalent, Inc. (NYSE:CTLT - Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 11,418 shares of the company's stock, valued at approximately $692,000.

Other institutional investors have also modified their holdings of the company. Brooklyn Investment Group purchased a new stake in Catalent during the third quarter worth approximately $31,000. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in Catalent during the 2nd quarter valued at $42,000. Sentry Investment Management LLC acquired a new position in Catalent in the 3rd quarter worth $53,000. Longfellow Investment Management Co. LLC boosted its position in Catalent by 45.7% in the 2nd quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company's stock valued at $55,000 after buying an additional 305 shares during the last quarter. Finally, GAMMA Investing LLC grew its stake in shares of Catalent by 25.9% during the second quarter. GAMMA Investing LLC now owns 1,032 shares of the company's stock valued at $58,000 after acquiring an additional 212 shares in the last quarter.

Insider Activity at Catalent

In other news, Director Michelle R. Ryan sold 2,800 shares of the company's stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $59.70, for a total transaction of $167,160.00. Following the completion of the transaction, the director now owns 10,835 shares in the company, valued at approximately $646,849.50. This represents a 20.54 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider David Mcerlane sold 1,994 shares of Catalent stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $59.97, for a total transaction of $119,580.18. Following the completion of the sale, the insider now owns 36,304 shares in the company, valued at approximately $2,177,150.88. This represents a 5.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 5,114 shares of company stock valued at $305,931 in the last quarter. Insiders own 0.31% of the company's stock.

Wall Street Analysts Forecast Growth

CTLT has been the topic of several recent analyst reports. Robert W. Baird reiterated a "neutral" rating and issued a $63.50 price target on shares of Catalent in a research note on Tuesday, September 24th. William Blair reaffirmed a "market perform" rating on shares of Catalent in a research report on Tuesday, September 3rd. StockNews.com cut Catalent from a "hold" rating to a "sell" rating in a research note on Friday, November 22nd. Finally, Baird R W lowered shares of Catalent from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, September 24th. One analyst has rated the stock with a sell rating and seven have issued a hold rating to the company's stock. According to MarketBeat, Catalent presently has an average rating of "Hold" and a consensus target price of $63.40.

Catalent Stock Performance

Shares of NYSE CTLT traded up $0.11 during trading on Friday, reaching $61.11. The stock had a trading volume of 771,192 shares, compared to its average volume of 1,870,216. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.96 and a current ratio of 2.51. The stock has a market cap of $11.09 billion, a PE ratio of -27.04, a P/E/G ratio of 2.43 and a beta of 1.16. Catalent, Inc. has a one year low of $36.74 and a one year high of $61.50. The firm's 50 day moving average price is $59.90 and its two-hundred day moving average price is $58.51.

Catalent (NYSE:CTLT - Get Free Report) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of $0.05 by ($0.18). Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The business had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.06 billion. During the same period in the prior year, the firm earned ($0.10) EPS. The business's revenue for the quarter was up 4.2% compared to the same quarter last year. On average, research analysts forecast that Catalent, Inc. will post 0.84 earnings per share for the current fiscal year.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.